Dyspnea in cancer patient
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) written consent (2) inpatient or outpatient (3) localy advanced or metastatic disease (4)prescribed SR oxycodone 20-200mg/day for regular analgesics (5) clinically clear consiousness (6) intensity of dyspnea in rest more than 3 in NRS (7) SpO2 > 90%, with supplimental oxygen if needed (8) ECOG PS 0-3
Exclusion criteria
Exclusion criteria: (1) anemia is a cause of dyspnea (2) acute respiratory failure (3) decompensated heart failure (4) impairment of liver function: 5 times higher than upper normal value of AST or ALT, or total bilirubin > 2mg/dl (5) renal insufficiency : twice higher than upper normal value of Cr (6) bacterial enteritis (7) unstable pain: more than 5 in NRS(0-10) and plan to increase opioid within next 24hr (8) expected prognosis is less than 1 month (9) hypersensitivity to opium alkaloid (10) opioid rescue use for pain within 9 hour before taking investigational drug (11) opioid analgesic use for any symptoms other than pain within 24 hour before taking investigational drug (12) history of taking opioid rescue for dyspnea (13) prescribed codein, morphine, fentanyl, tramadol, or buprenorphine as regular medication (14) those who is considered not to be qualified for this trial by primary responsible doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean change in intensity of dyspnea evaluated by NRS at 60 minutes after taking investigational drug in each group. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) mean change in intensity of dyspnea evaluated by NRS at 120 minutes after taking investigational drug in each group. (2)the rate of the patietnts with more than 1 reduction in dyspnea intensity evaluated by NRS at 60 and 120 minutes after taking investigational drug in each group. | — |
Countries
Japan
Contacts
Kobe University hospital Department of Palliative Medicine